bioAffinity Technologies' Patent Breakthrough: Dual-Receptor Cancer Targeting Enters New Phase

bioAffinity Technologies has secured a significant intellectual property milestone with the U.S. Patent and Trademark Office awarding Patent No. 12,305,171 for a groundbreaking cancer treatment approach. The innovation centers on simultaneous suppression of CD320 and LRP2 receptors—two cellular markers that, when knocked down together, demonstrate selective destruction of malignant cells while preserving healthy tissue.

The Science Behind the Discovery

The therapeutic mechanism employs small interfering RNAs (siRNAs) to suppress protein expression at the cellular level. Laboratory investigations revealed a critical finding: when researchers targeted only one receptor, compensatory protein expression increased in the other. However, simultaneous dual knockdown of CD320 and LRP2 triggers selective cytotoxicity specifically in cancer cells, effectively blocking proliferation without collateral damage to normal cells.

“The cancer cells eliminated through this discovery weren’t pre-selected by any particular biomarker,” explained William Bauta, PhD, Chief Science Officer at bioAffinity Technologies. “The effect appears remarkably universal, suggesting we’ve identified a fundamental weakness in cancer biology that multiple therapeutic strategies could potentially exploit.”

Expanding Clinical Applications

The patent protection extends across multiple cancer types, including lung, breast, prostate, brain, and cutaneous malignancies. bioAffinity Technologies is prioritizing topical formulation development targeting skin cancer treatment—an area where localized application could offer clinical advantages and faster therapeutic delivery.

This intellectual property addition strengthens the company’s existing portfolio of 19 awarded U.S. and international patents, alongside 36 pending applications spanning diagnostic platforms and cancer treatment interventions.

Connecting to Existing Diagnostic Excellence

The therapeutic advancement builds naturally from bioAffinity Technologies’ established diagnostic platform. CyPath® Lung, the company’s flagship product, demonstrates the precision-medicine approach with 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer among high-risk patients with nodules under 20 millimeters. This diagnostic achievement establishes proof-of-concept for the company’s ability to identify and address cancer at earliest intervention points.

Maria Zannes, President and CEO at bioAffinity Technologies, contextualized the development: “This patent represents meaningful advancement in our therapeutic pipeline and strengthens our intellectual property position. The discovery extends the scientific investigation that led to CyPath® Lung diagnostics and creates multiple pathways for precision treatment strategies across diverse cancer presentations.”

Market Positioning and Next Steps

The dual-receptor targeting mechanism operates independently of traditional cancer biomarkers, potentially broadening treatment applicability beyond conventional patient stratification approaches. The move from in vitro validation to topical skin cancer formulation represents bioAffinity Technologies’ strategy for nearterm clinical translation while supporting longer-term systemic cancer treatment development.